Want to see HK:2500 full AI Analyst Report?
2500 Stock Chart & Stats
HK$2.46
HK$0.00(0.00%)
At close: 4:00 PM EDT
HK$2.46
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$1.01 - HK$5.47
Previous CloseN/A
Volume6.42M
Average Volume (3M)2.48M
Market Cap
HK$498.34M
Enterprise ValueHK$970.85
Total Cash (Recent Filing)HK$280.52M
Total Debt (Recent Filing)HK$216.43M
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding441,010,220
10 Day Avg. Volume2,133,843
30 Day Avg. Volume2,483,027
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.53
Price to Sales (P/S)3.05
P/FCF Ratio-2.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.25
Revenue Forecast (FY)HK$791.75M
Bulls Say, Bears Say
Bulls Say
Specialized TAVI And Interventional PortfolioA focused product set around transcatheter aortic valve implantation and related interventional devices anchors the business in a structural-growth medical niche. Durable demand for minimally invasive structural heart solutions supports long-term procedure volume and hospital adoption, enabling sustained revenue potential if market share is preserved.
Improving Balance-sheet LeverageMaterial reduction in leverage to a low debt-to-equity ratio improves financial flexibility, lowers refinancing risk, and gives management scope to fund operations or R&D without immediate pressure. For a cash-burning med-tech, stronger balance-sheet metrics extend runway and reduce probability of disruptive financing needs over the medium term.
Still-solid Gross Margin LevelsPreserved gross margins indicate underlying unit economics and pricing power in core products. That structural margin strength means cost control or revenue recovery could translate more directly into operating leverage and eventual profitability, making margin sustainability a viable pathway to turn operating losses into positive results over time.
Bears Say
Sharp Revenue DeclineA near-30% revenue drop materially weakens scale economics and strains the fixed-cost base typical in med-tech commercial models. Sustained top-line contraction reduces bargaining power with hospitals and distributors, delays breakeven, and makes investment in market expansion or clinical adoption more costly, threatening medium-term viability.
Persistent Operating And Net LossesChronic operating and net losses erode equity and limit retained-capital resources for sales, clinical trials, and product development. Without a clear, sustained path to operating profitability, the firm will likely require continued external funding, which could dilute shareholders and constrain strategic autonomy over the coming quarters.
Weak Cash Generation / Cash BurnRecurrent negative operating and free cash flow heighten reliance on external financing and increase refinancing and dilution risk. For a company in a capital-intensive adoption phase, persistent cash burn constrains sustained commercial investments and raises existential funding risk if revenue recovery or profitability is delayed.
Venus Medtech (Hangzhou), Inc. Class H News
2500 FAQ
What was Venus Medtech (Hangzhou), Inc. Class H’s price range in the past 12 months?
Venus Medtech (Hangzhou), Inc. Class H lowest stock price was HK$1.01 and its highest was HK$5.47 in the past 12 months.
What is Venus Medtech (Hangzhou), Inc. Class H’s market cap?
Venus Medtech (Hangzhou), Inc. Class H’s market cap is HK$498.34M.
When is Venus Medtech (Hangzhou), Inc. Class H’s upcoming earnings report date?
Venus Medtech (Hangzhou), Inc. Class H’s upcoming earnings report date is Aug 27, 2026 which is in 24 days.
How were Venus Medtech (Hangzhou), Inc. Class H’s earnings last quarter?
Venus Medtech (Hangzhou), Inc. Class H released its earnings results on Mar 31, 2026. The company reported -HK$0.682 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Venus Medtech (Hangzhou), Inc. Class H overvalued?
According to Wall Street analysts Venus Medtech (Hangzhou), Inc. Class H’s price is currently Overvalued.
Does Venus Medtech (Hangzhou), Inc. Class H pay dividends?
Venus Medtech (Hangzhou), Inc. Class H does not currently pay dividends.
What is Venus Medtech (Hangzhou), Inc. Class H’s EPS estimate?
Venus Medtech (Hangzhou), Inc. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Venus Medtech (Hangzhou), Inc. Class H have?
Venus Medtech (Hangzhou), Inc. Class H has 441,010,220 shares outstanding.
What happened to Venus Medtech (Hangzhou), Inc. Class H’s price movement after its last earnings report?
Venus Medtech (Hangzhou), Inc. Class H reported an EPS of -HK$0.682 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.543%.
Which hedge fund is a major shareholder of Venus Medtech (Hangzhou), Inc. Class H?
Currently, no hedge funds are holding shares in HK:2500
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Venus Medtech (Hangzhou), Inc. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.31%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-18.86%
Trailing 12-Months
Company Description
Venus Medtech (Hangzhou), Inc. Class H
Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company’s offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to treat the patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis. It also develops Venus-Vitae, a balloon-expandable dry-tissue product; Venus-PowerX, a self-expanding dry-tissue product; Cardiovalve, a transcatheter valve replacement system for the treatment of patients with mitral regurgitation and in pivotal clinical trial for the treatment of patients with tricuspid regurgitation; Liwen RF, a radiofrequency ablation system for the treatment of hypertrophic cardiomyopathy; and renal artery denervation ablation system for the treatment of hypertension. In addition, the company offers procedural accessories comprising catheter sheath product and balloon catheter. Venus Medtech (Hangzhou) Inc. was incorporated in 2009 and is headquartered in Hangzhou, the People’s Republic of China.
Technical Analysis
MicroPort Scientific
―
MicroPort CardioFlow Medtech Corp.
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
―
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
―